Tyra Biosciences, Inc. (TYRA) Form 8-K — Aug 4, 2026
Tyra Biosciences reported a second quarter 2026 net loss of $45.6 million versus $28.1 million a year earlier, with R&D expense up 61% to $39.2 million as it advanced three Phase 2 trials of oral dabogratinib, and G&A up to $9.8 million from $7.1 million on headcount growth. The company ended the quarter with $353.9 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2028. It also amended its at-the-market sales agreement with TD Securities, adding capacity to sell up to an additional $250.0 million of common stock.
Key figures
- Guidance
- Cash, cash equivalents and marketable securities expected to fund operations into the second half of 2028
- Total Assets
- 383362000
- Cash Position
- 353900000
- Net loss q2 2025
- 28098000
- Surf302 enrolled
- >40 patients
- Total liabilities
- 29698000
- Ga expense q2 2025
- 7143000
- Ga expense q2 2026
- 9806000
- Rnd expense q2 2025
- 24309000
- Rnd expense q2 2026
- 39197000
- Marketable securities
- 280109000
- Dabogratinib studied in
- more than 200 individuals
- Net loss six months 2026
- 84863000
- Cash and equivalents only
- 73835000
- Atm additional capacity usd
- 250000000
- Weighted avg shares q2 2026
- 65991171
- Beach301 dose level 5 dosing
- 0.625 mg/kg
- Beach301 dose levels cleared
- 4
- Beach301 sentinel cohort children
- ~25
Price after filing
Close on the filing date to close N calendar days later (from $32.04). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.